Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immuno deficiency Virus

MMWR August 5, 1994 Executive Committee and U.S. Public Health Service Task Force On June 6, 1994, the U.S. Public Health Service convened a workshop in Bethesda, Maryland, to develop recommendations for the use of zidovudine to reduce the risk for perinatal transmission of human immunodeficiency virus (HIV). The recent results of AIDS Clinical Trials Group Protocol 076, a controlled clinical trial sponsored by the National Institutes of Health in collaboration with the National Institute of Health and Medical Research and the National Agency of Research on AIDS in France, indicate that zidovudine administered to a selected group of HIV-infected women and their infants can reduce the risk for perinatal transmission of HIV by approximately twothirds. The implications of these results for use of zidovudine in HIV-infected pregnant women and neonates were discussed at the workshop. The following persons participated in the workshop and either served as the Executive Committee writing group that developed the recommendations or were members of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal HIV Transmission. Executive Committee Howard L. Minkoff, M.D. (co-chair) State University of New York Brooklyn, NY Arlene D. Bardeguez, M.D. New Jersey Medical School Newark, NJ Yvonne J. Bryson, M.D. University of California at Los Angeles Los Angeles, CA Isaac Delke, M.D. University of Florida College of Medicine Jacksonville, FL Clemente Diaz, M.D. University of Puerto Rico School of Medicine San Juan, PR Joep M.A. Lange, M.D. World Health Organization Geneva, Switzerland Michael K. Lindsay, M.D., M.P.H. Emory University Atlanta, GA Wade Parks, M.D. (co-chair) New York University School of Medicine New York, NY Paul Meier, Ph.D. Columbia University New York, NY Angus Nicoll, M.D. Communicable Disease Surveillance Centre London, England Mary J. O'Sullivan, M.D. University of Miami Miami, FL Sallie M. Perryman New York State Department of Health New York, NY Gwendolyn B. Scott, M.D. University of Miami School of Medicine Miami, FL Diane W. Wara, M.D. University of California at San Francisco San Francisco, CA

/ 28

Actions

file_download Download Options Download this page PDF - Pages #1-28 Image - Page ii Plain Text - Page ii

About this Item

Title
Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immuno deficiency Virus
Author
Centers for Disease Control and Prevention (U.S.)
Canvas
Page ii
Publication
Centers for Disease Control (U.S.)
1994-08-05
Subject terms
reports
Item type:
reports

Technical Details

Link to this Item
https://name.umdl.umich.edu/5571095.0283.005
Link to this scan
https://quod.lib.umich.edu/c/cohenaids/5571095.0283.005/4

Rights and Permissions

The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.

Manifest
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0283.005

Cite this Item

Full citation
"Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immuno deficiency Virus." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0283.005. University of Michigan Library Digital Collections. Accessed June 4, 2025.
Do you have questions about this content? Need to report a problem? Please contact us.

Downloading...

Download PDF Cancel